Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Event, Product/Service, Webcast

Verge Genomics to Present at Upcoming Investor Conferences in November


Verge Genomics, a clinical-stage, tech-enabled biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform drug discovery, announced today that Alice Zhang, CEO and co-founder of Verge Genomics, will present at both the Piper Sandler 34th Annual Healthcare Conference on November 29 in New York, and the 5th Annual Evercore ISI HealthCONx Conference 2022 on November 30. Please see additional information below:

Piper Sandler 34th Annual Healthcare Conference

5th Annual Evercore ISI HealthCONx Conference 2022

About Verge Genomics

Verge uses AI and human data to develop better drugs faster for the most challenging diseases of our generation. Verge has built CONVERGEtm, an end-to-end drug discovery and development platform, that integrates multiple technological innovations from discovery to translation to streamline drug development. Its pioneering use of the industry's most advanced all-in-human, AI-powered drug discovery platform identifies new medicines more efficiently and with an improved probability of success.

Verge is one of the first AI-enabled drug discovery companies to independently develop a clinical candidate from a novel target discovered from its platform. Verge has further demonstrated the power of CONVERGEtm by delivering a broad pipeline spanning diverse therapeutic areas, with its first program, an investigational PIKfyve inhibitor for the treatment of ALS, now in the clinic. The company is led by experienced drug developers and computational biologists with a shared belief that technology has created a new opportunity to deliver life-changing medicines more efficiently.

For additional information, please visit VergeGenomics.com. Follow us on LinkedIn and Twitter.


These press releases may also interest you

at 14:20
Gastroesophageal Reflux Disease (GERD) Market size is set to grow by USD 879.8 million from 2024-2028, Rising geriatric population to boost the market growth, Technavio
The global gastroesophageal reflux disease (GERD) market  size is estimated to grow by USD 879.8 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  3.2%  during the forecast period.  Rising geriatric...

at 12:48
Pendopharm signs exclusive distribution agreement with Ascendis Pharma A/S for TransContm PTH in Canada
Pendopharm, a division of Pharmascience Inc., announced today that it has signed an exclusive distribution agreement with Ascendis Pharma A/S ("Ascendis"), a global biopharmaceutical company headquartered in Copenhagen, Denmark. Under the terms of...

at 12:36
IMPERIAL TOBACCO CANADA ADVOCATES FOR A NEW FEDERAL FRAMEWORK THAT TREATS ALL NICOTINE REPLACEMENT THERAPIES (NRTs) EQUALLY
Imperial Tobacco Canada Limited ("ITCAN") has officially submitted its feedback to Health Canada regarding the proposed Ministerial Order on nicotine replacement therapy products (NRTs). ITCAN strongly believes that NRTs, especially innovative...

at 12:20
Global Regenerative Medicine Partnering Deals Analysis Report and Directory 2016-2024: 1771 Collaboration, Development, Research and Licensing Deals by Company A-Z, Deal Type and Therapy Area - ResearchAndMarkets.com
The "Regenerative Medicine Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Regenerative Medicine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented...

at 12:10
Diagnostic Imaging Partnering Analysis Report and Directory 2016-2024: 628 Collaboration, Development, Research and Licensing Deals by Company A-Z, Deal Type and Therapy Area - ResearchAndMarkets.com
The "Diagnostic Imaging Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Diagnostic Imaging Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to...

at 12:05
KFSH&RC Achieves Remarkable 98% Survival Rate in 400 Robotic Cardiac Surgeries
King Faisal Specialist Hospital & Research Centre (KFSH&RC) has achieved a significant milestone in its Robotic Cardiac Surgery Program, which was initiated in February 2019. Within its first year, the program performed 105 cardiac procedures. As of...

More news about Health...


News published on and distributed by: